Molecular Partners (MOLN) Q1 2026 earnings summary

Executive summary

• Initiated two clinical studies in Q1 2026: MP0712 (Radio-DARPin) and MP0317 (tumor-localized CD40 agonist).

• MP0712 Phase 1/2a trial recruiting at four sites, with initial data expected in 2026.

• MP0317 Phase 2 study in advanced cholangiocarcinoma ongoing at eight sites in France.

• MP0533 Phase 1/2a trial for AML fully recruited in dose escalation, with promising remission data.

• Corporate governance strengthened with new board member Clare Fisher.

Financial highlights

• Cash and short-term time deposits totaled CHF 79 million (approx. USD 100 million) as of March 31, 2026.

• Net loss for Q1 2026 was CHF 13.1 million, compared to CHF 16.8 million in Q1 2025.

• Operating expenses decreased to CHF 13.4 million from CHF 16.1 million year-over-year.

• Net cash used in operating activities was CHF 14.2 million, down from CHF 17.1 million in Q1 2025.

• Shareholders’ equity stood at CHF 68.5 million as of March 31, 2026.

Outlook and guidance

• Cash runway expected to fund operations into late 2027, reflecting increased R&D investment.

• Initial clinical data from MP0712 Phase 1/2a anticipated in 2026.

• MP0726 (mesothelin-targeting RDT) to enter first-in-human imaging in H2 2026.

• New Radio-DARPin target nomination expected in H2 2026.